Clinical Trial

Emodepside Phase II Trial for Treatment of Onchocerciasis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-12-17.
Status change: Recruiting → Active, Not Recruiting 2024-03-04
Trial Details
NCT Number NCT05180461
Lead Sponsor Drugs for Neglected Diseases
Collaborators: Bayer
Conditions Onchocerciasis
Enrollment 578 participants
Start Date 2021-08-30
Primary Completion 2026-09-18 (estimated)
Study Completion 2026-10-02 (estimated)
Updated on ClinicalTrials.gov 2024-03-05